Precision Oncology: The Road Ahead

Overview

Journal Trends Mol Med

Specialties General Medicine
Molecular Biology

Date 2017 Sep 10

PMID 28887051

Citations 77

Authors

Daniela Senft

Mark D M Leiserson

Eytan Ruppin

Zeev A Ronai

Affiliations

Soon will be listed here.

Abstract

Current efforts in precision oncology largely focus on the benefit of genomics-guided therapy. Yet, advances in sequencing techniques provide an unprecedented view of the complex genetic and nongenetic heterogeneity within individual tumors. Herein, we outline the benefits of integrating genomic and transcriptomic analyses for advanced precision oncology. We summarize relevant computational approaches to detect novel drivers and genetic vulnerabilities, suitable for therapeutic exploration. Clinically relevant platforms to functionally test predicted drugs/drug combinations for individual patients are reviewed. Finally, we highlight the technological advances in single cell analysis of tumor specimens. These may ultimately lead to the development of next-generation cancer drugs, capable of tackling the hurdles imposed by genetic and phenotypic heterogeneity on current anticancer therapies.

Citing Articles

Computational frameworks transform antagonism to synergy in optimizing combination therapies.

Chen J, Lin A, Jiang A, Qi C, Liu Z, Cheng Q NPJ Digit Med. 2025; 8(1):44.

PMID: 39828791 PMC: 11743742. DOI: 10.1038/s41746-025-01435-2.

From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients.

Guo Y, Li T, Gong B, Hu Y, Wang S, Yang L Adv Sci (Weinh). 2024; 12(2):e2408069.

PMID: 39535476 PMC: 11727298. DOI: 10.1002/advs.202408069.

Molecular and modular intricacies of precision oncology.

Chhabra R Front Immunol. 2024; 15:1476494.

PMID: 39507541 PMC: 11537923. DOI: 10.3389/fimmu.2024.1476494.

The expression patterns of different cell types and their interactions in the tumor microenvironment are predictive of breast cancer patient response to neoadjuvant chemotherapy.

Dhruba S, Sahni S, Wang B, Wu D, Rajagopal P, Schmidt Y bioRxiv. 2024; .

PMID: 39372749 PMC: 11451622. DOI: 10.1101/2024.06.14.598770.

Examining external control arms in oncology: A scoping review of applications to date.

Farah E, Kenney M, Warkentin M, Cheung W, Brenner D Cancer Med. 2024; 13(13):e7447.

PMID: 38984669 PMC: 11234289. DOI: 10.1002/cam4.7447.

References

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Szczurek E, Misra N, Vingron M . Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma. Int J Cancer. 2013; 133(9):2123-32. DOI: 10.1002/ijc.28235. View

Huang F, Hodis E, Xu M, Kryukov G, Chin L, Garraway L . Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339(6122):957-9. PMC: 4423787. DOI: 10.1126/science.1229259. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

van Leeuwen J, Pons C, Mellor J, Yamaguchi T, Friesen H, Koschwanez J . Exploring genetic suppression interactions on a global scale. Science. 2016; 354(6312). PMC: 5562937. DOI: 10.1126/science.aag0839. View

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

Zhu J, Sammons M, Donahue G, Dou Z, Vedadi M, Getlik M . Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525(7568):206-11. PMC: 4568559. DOI: 10.1038/nature15251. View

Hoadley K, Yau C, Wolf D, Cherniack A, Tamborero D, Ng S . Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158(4):929-944. PMC: 4152462. DOI: 10.1016/j.cell.2014.06.049. View

Schwaederle M, Parker B, Schwab R, Daniels G, Piccioni D, Kesari S . Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016; 15(4):743-52. DOI: 10.1158/1535-7163.MCT-15-0795. View

10.

Drake J, Paull E, Graham N, Lee J, Smith B, Titz B . Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell. 2016; 166(4):1041-1054. PMC: 4985183. DOI: 10.1016/j.cell.2016.07.007. View

11.

Hartwell L, Szankasi P, Roberts C, Murray A, Friend S . Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997; 278(5340):1064-8. DOI: 10.1126/science.278.5340.1064. View

12.

Hofree M, Shen J, Carter H, Gross A, Ideker T . Network-based stratification of tumor mutations. Nat Methods. 2013; 10(11):1108-15. PMC: 3866081. DOI: 10.1038/nmeth.2651. View

13.

Van Allen E, Lui V, Egloff A, Goetz E, Li H, Johnson J . Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015; 1(2):238-44. PMC: 4557203. DOI: 10.1001/jamaoncol.2015.34. View

14.

Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear E, Sevier C . The genetic landscape of a cell. Science. 2010; 327(5964):425-31. PMC: 5600254. DOI: 10.1126/science.1180823. View

15.

Vargas A, Harris C . Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer. 2016; 16(8):525-37. PMC: 6662593. DOI: 10.1038/nrc.2016.56. View

16.

Wang X, Fu A, McNerney M, White K . Widespread genetic epistasis among cancer genes. Nat Commun. 2014; 5:4828. DOI: 10.1038/ncomms5828. View

17.

Vandin F, Raphael B, Upfal E . On the Sample Complexity of Cancer Pathways Identification. J Comput Biol. 2015; 23(1):30-41. PMC: 4700400. DOI: 10.1089/cmb.2015.0100. View

18.

Rathert P, Roth M, Neumann T, Muerdter F, Roe J, Muhar M . Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015; 525(7570):543-547. PMC: 4921058. DOI: 10.1038/nature14898. View

19.

Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R . A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-83. PMC: 2665285. DOI: 10.1038/nrc1299. View

20.

Wagle N, Grabiner B, Van Allen E, Hodis E, Jacobus S, Supko J . Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014; 4(5):546-53. PMC: 4122326. DOI: 10.1158/2159-8290.CD-13-0353. View